Accession Number:

ADA510149

Title:

Beta-catenin/TCF Signaling and Castrate-Resistant Progression of Osteoblastic Bone Metastases

Descriptive Note:

Annual rept. 12 May 2008-11 May 2009

Corporate Author:

M D ANDERSON CANCER CENTER HOUSTON TX

Personal Author(s):

Report Date:

2009-06-01

Pagination or Media Count:

11.0

Abstract:

In this project, we are studying the role of D32G-mutant beta-catenin in the expression of secretory genes by prostate cancer cells. We believe that D32G-mutant beta-catenin potently activates a subset of beta-cateninwnt downstream target genes, thus providing a tool for identifying bone progression factors activated by this pathway in prostate cancer. Results from the studies performed during this period indicate that activation of beta-catenin in prostate cancer cells stimulates a subset of beta-catenin target genes and suggest that beta-catenin expression in prostate cancer cells mediates the prostate cancerinduced new bone formation in vitro and in vivo. These results provide confidence that our gene-expression studies will be informative for identifying the beta-catenin downstream target genes that mediate the osteoblastic phenotype induced by prostate cancer cells. Immunohistochemical studies performed in human bone metastases of prostate cancer identified 4 groups based on beta-catenin intracellular distribution and expression and androgen receptor expression. It will be interesting to assess how the selected factors induced by beta-catenin in prostate cancer cells are expressed in the different groups. Although these results would only be correlative, they would provide the basis for prioritization in future studies.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE